Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_837_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
38 Мб
Скачать
60 Familial Adenomatous Polyposis
467
Syngal S, Brand RE, Church JM, Giardiello FM,
Hampel HL, Burt RW, etal. ACG clinical guideline: genetic testing and management of hereditary gas­trointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62; quiz 63.
Steinhagen E, Guillem JG, Chang G, Salo-Mullen
EE, Shia J, Fish S, etal. The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. Clin Colorectal Cancer. 2012;11(4):304–8.
Vitellaro M, Sala P, Signoroni S, Radice P, Fortuzzi
S, Civelli EM, et al. Risk of desmoid tumours after open and laparoscopic colectomy in patients with familial adenomatous polyposis. Br J Surg. 2014;101(5):558–65.
Vasen HF, Moslein G, Alonso A, Aretz S, Bernstein I,
Bertario L, etal. Guidelines for the clinical manage­ment of familial adenomatous polyposis (FAP). Gut. 2008;57(5):704–13.

Colonic Conditions: Lynch Syndrome

MatthewF.Kalady
61
Denitions andClassication ofTerms
Lynch syndrome is dened by the presence of a pathogenic variant in one of the mismatch repair (MMR) genes MLH1, MSH2, MSH6, PMS2. Rarely, Lynch syndrome is caused by a mutation in EPCAM. The diagnosis is based on genetic test results. The germline mutation is heritable and dominant with the resultant phe­notype marked by increased risk of colorectal and extracolonic cancers, which arise at a young age. The most common cancers associ­ated with Lynch syndrome include colorectal, endometrial, ovarian, gastric, urinary epithelial, small bowel, pancreas, and skin. The gene mutations in Lynch syndrome result in lack of MMR protein expression and function and thus tumors are characterized by MMR deciency (MMRd). MMRd is characterized molecularly by high microsatellite instability (MSI-H).
Before the exact genetic etiology was iden­tied, clinicians and researchers developed clinical criteria to help identify, treat, and study patients who had commonly associated cancers that were prevalent in their families and at young ages. These criteria were developed at a
M. F. Kalady (*) Department ofColorectal Surgery, Cleveland Clinic, Cleveland, OH, USA e-mail: kaladym@ccf.org
meeting in Amsterdam and were thus termed Amsterdam criteria. Amsterdam II criteria include the following: (1) there should be at least 3 relatives with a Hereditary Nonpolyposis Colorectal Cancer (HNPCC)-related cancer; (2) at least two successive generations should be affected; (3) at least one affected individual is diagnosed before age 50; (4) Familial adeno­matous polyposis is excluded. HNPCC-related cancers include those of the colorectum, endo­metrial, ovaries, stomach, small intestine, ure­ter or renal pelvis, pancreas, hepatobiliary system, brain, and skin sebaceous neoplasms. Affected people from families meeting Amsterdam criteria are diagnosed as having HNPCC.HNPCC by itself, does not diagnose Lynch syndrome, but rather identies people at increased risk for cancer and those that should be evaluated for Lynch syndrome by genetic testing. Not all patients with Lynch syndrome have HNPCC, and not all HNPCC patients will have Lynch syndrome. Patients with HNPCC but without a germline conrmation of Lynch syndrome are at increased risk compared to the general population, but not as high as those with Lynch syndrome.
As stated above, MSI is the molecular hall­mark of Lynch syndrome tumors. Patients whose families meet Amsterdam criteria but have a microsatellite stable tumor are diag­nosed with Familial Colorectal Cancer Type X (FCC X). The people have an increased risk of
© Springer Nature Switzerland AG 2020 S. R. Steele etal. (eds.), Clinical Decision Making in Colorectal Surgery,
https://doi.org/10.1007/978-3-319-65942-8_61
469
470
M. F. Kalady
cancer compared to the general population, but not as high at those with Lynch syndrome and cancers develop at a later age compared to those with Lynch syndrome. This chapter focuses on the algorithmic approach to the diagnosis and management of Lynch syndrome.
Refer toAlgorithm inFig. 61.1
Presentation andClinical Situations
A. Lynch syndrome evaluation and manage-
ment depends on the clinical situation. Patients mainly either present with a lesion (i.e., colorectal adenoma or cancer, or extracolonic cancer) and a diagnosis needs to be made; or patients present with a Lynch syndrome diagnosis after undergoing coun­seling and genetic testing due to a relative being diagnosed with Lynch syndrome. Both of these situations are discussed in the algorithm.
Suspected Lynch Syndrome
B. Detailed Personal and Family History
Since Lynch syndrome is a genetic pre­disposition to multiple cancers both in the individual and in the family, a detailed per­sonal and family history is mandatory. An adequate family history should include information on family members from at least 3 generations. The collection of infor­mation always starts with the current patient, and expands primarily to rst­degree relatives, but also should include second- and third-degree relatives. For each family member, the presence of colorectal polyps, colorectal cancers, and any extra­colonic cancers should be recorded, includ­ing the age at which each lesion was detected. A family tree or pedigree drawing allows for a visual representation of the cancers within a family and can be used to analyze particular trends or inheritance pat­terns within the family. A written pedigree
Fig. 61.1 Algorithm. Abbreviations: MSI microsatellite instability, MSI-H high microsatellite instability, MMR mismatch repair, MMRd mismatch repair deciency, IHC
immunohistochemistry, TAH total abdominal hysterec­tomy, BSO bilateral salpingo-oophorectomy, IPAA ileal pouch-anal anastomosis
61 Colonic Conditions: Lynch Syndrome
471
also creates a structure that can be easily updated as new information becomes avail­able. It is important to note that the family history is only as accurate as the source and the history should be validated by medical records when possible.
Patients with a history suggestive of Lynch syndrome should be evaluated further. Multiple guidelines have been developed as a way to identify who should undergo addi­tional testing. Amsterdam criteria, as dis­cussed above, have been widely used. Amsterdam II criteria are fairly sensitive at about 85% for identifying Lynch syndrome, but are only about 20% specic. The revised Bethesda guidelines utilize history as well as tumor histologic ndings to determine who should undergo tumor MSI testing as a screen of Lynch. Revised Bethesda criteria are the following: (1) colorectal cancer diagnosed in a patient who is less than 50years of age; (2) the presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors, regardless of age; (3) colorectal can­cer with the MSI-H histology diagnosed in a patient who is less than 60years of age; (4) colorectal cancer diagnosed in one or more rst-degree relatives with an HNPCC-related tumor, with one of the cancers being diag­nosed under age 50years; (5) colorectal can­cer diagnosed in two or more rst- or second-degree relatives with HNPCC-related tumors, regardless of age.
Since the goal is to identify and survey patients before cancers develop, it is prudent to be more suspicious. In general, the author favors a low threshold to pursue additional evaluation for Lynch syndrome even if they do not meet all of the suggested criteria. The National Comprehensive Cancer Network recommends that colorectal cancers resected from all patients under the age of 70 undergo tumor testing as a screen for Lynch syndrome.
C. Tumor Testing
As mismatch repair deciency (MMRd) is the underlying cause of Lynch syndrome, the rst line of screening includes testing the
tumor for MMRd. Tumor testing for MMR deciency is more accurate and cost-effective at identifying potential Lynch syndrome patients compared to clinical criteria alone. The two ways of identifying MMRd are MSI in the tumor, or by measuring mismatch repair protein expression using immunohisto­chemistry (IHC). MSI is a PCR-based test using tumor DNA.IHC is an antibody based test applied to tumor sections on a slide. More than 90% of Lynch syndrome CRC will be MSI-H and lack of MMR protein expression.
Only about 15% of MMRd tumors result from the germline variants of Lynch syn­drome. Across all colorectal cancers, micro­satellite instability is most commonly caused by hypermethylation of the DNA promoter region of the MLH1 gene which results in lack of expression and function MLH1 and thus results in MMRd. Thus, if MLH1 expression is lost on IHC, it is more com­monly the result of hypermethylation rather than Lynch syndrome, depending on the clin­ical situation. Two tumor tests are commonly used to distinguish the difference between sporadic and Lynch-associated MLH1 loss. Hypermethylation of the promoter region can be measured directly. Secondly, tumors can be tested for a mutation in the BRAF oncogene. Most sporadic MMRd tumors have BRAF mutations. Thus, mutated BRAF is more consistent with a sporadic tumor, while wild-type BRAF suggests additional evaluation for Lynch syndrome. If expres­sion of one of the other MMR proteins (MSH2, MSH6, or PMS2) is lost, then genetic testing for that specic associated gene is done.
Tumor testing is ideally done on the tumor biopsy at the time of cancer diagnosis so that appropriate work-up and evaluation can be done before surgery. A known diagnosis of Lynch syndrome affects surgical manage­ment (see below). Unfortunately, it is often not practical or feasible to perform tumor testing on every single colorectal cancer prior to surgery. However, if there is suspicion for Lynch or another hereditary colorectal cancer
472
M. F. Kalady
syndrome, preoperative tumor testing with subsequent genetic counseling and testing as appropriate should be done. Examples where preoperative tumor testing should be done include patients meeting Amsterdam criteria, histologic ndings suggestive of Lynch syn­drome, or colorectal cancer at a young age.
D. Genetic Counseling
If tumor testing is consistent with a possi­ble Lynch syndrome diagnosis, genetic coun­seling is recommended. These services are most appropriately provided by a medical geneticist or genetic counselor. Based on the personal and family history, counselors can determine which genetic test is most appro­priate (if any) and also which family mem­bers should be tested. Counseling should provide an overview of the suspected syn­drome, the technical aspects and accuracy of the test, and the possible results. The discus­sion should include information about eco­nomic considerations, possibility of genetic discrimination, condentiality, utilization of test results, and alternatives to genetic testing. An assessment of the potential of psychoso­cial issues that may arise for patients and their families while going through this pro­cess is also essential. Lastly, there must be a plan in place to communicate the results. All of this information should empower patients to make an informed choice whether or not to undergo genetic testing. Due to the complex­ity and implications of the interpreting genetic test results, counseling should be per­formed by a trained professional.
E. Genetic Testing
After counseling, genetic testing is offered to the appropriate patients and conducted with informed consent. Germline testing is rou­tinely done on a blood sample, but can also be performed using saliva. There are multiple commercial vendors who perform these tests. When tumor testing is not available to isolate a particular gene for testing, other strategies are employed. Some counselors will test all four MMR genes. Recently, several commer­cial gene panel tests have been developed and utilized for broader identication of heredi­tary based cancers, including CRC.
Management ofLynch Syndrome
Surgical decision-making in Lynch syndrome patients with colorectal cancer is complex and involves consideration of oncologic principles, disease prognosis, future cancer risk reduction, expected functional outcomes and quality of life, and patient wishes. The cornerstone of treatment is the surgical resection of the cancer and the sur­rounding colon according to oncologic princi­ples. For sporadic colorectal cancers, resection is usually a segmental colectomy. However, for Lynch syndrome patients who develop colorectal cancer, the concept of extended colectomy as a prophylactic measure to remove more colon than would be removed for a simple segmental colec­tomy to reduce metachronous cancer risk is a guiding principle.
F. Surgical Management: Extended Resection
Multiple organizations including the National Comprehensive Cancer Network, The American Society of Colon and Rectal Surgeons, and a US Multi-Society Taskforce recommend extended colectomy for patients with colon cancer and Lynch syndrome. This recommendation is based mainly on the metachronous colon cancer risk. There are no randomized prospective trials comparing colorectal cancer risk after extended colec­tomy and segmental colectomy. However, there are multiple retrospective analyses that support signicant colon cancer risk reduc­tion after a total colectomy and ileorectal anastomosis compared to a segmental colec­tomy. For patients undergoing a segmental colectomy, the reported risk of metachronous cancer is approximately 16–25% at around 10 years. In one large international registry study, the risk was extrapolated over time and as expected increased to 16%, 41%, and 62% at 10, 20, and 30years, respectively. The risk of metachronous rectal cancer after colec­tomy and ileorectal anastomosis is approxi­mately 5–10% at 10years.
An argument against extended colectomy that is sometimes made is that colonoscopy can adequately survey and control neoplasia in any residual colon after a segmental colectomy.
61 Colonic Conditions: Lynch Syndrome
473
Again, there is no prospective data that sup­ports or refutes that statement. In fact, this may seem logical given that colonoscopy in Lynch syndrome patients without a cancer does reduce the incidence and death from colorectal cancer. However, there are several practical challenges to a successful postoperative sur­veillance regimen. In fact, interval cancers develop in 35% of cases under surveillance. Several factors may contribute to this phenom­enon such as poor patient compliance, poor quality colonoscopy, suboptimal bowel prepa­ration, experience of the endoscopist, and the more aggressive adenoma- to-carcinoma sequence seen in Lynch syndrome.
Non-cancer related considerations in sur­gical decision making are quality of life and bowel functional expectations. Proponents of segmental resection site concern over worse function as more bowel is removed. The data on this topic is also limited, but there seems to be a consensus that although a total colec­tomy yields more frequent bowel movements, the overall quality of life is not different com­pared to a segmental colectomy.
Decision-making for rectal cancer surgery in Lynch syndrome is more complex than colon cancer. Options include treating the pri­mary cancer alone by proctectomy, or an extended resection to remove all colorectal at­risk mucosa via a total proctocolectomy (TPC) with end ileostomy or restorative ileal pouch-anal anastomosis (IPAA). Proctectomy without colectomy leaves a substantial meta­chronous colon cancer risk of approximately 15–20% at 10years, even under surveillance. Again, the risk increases over time after resec­tion with metachronous colon cancer esti­mates at 47% at 20years, and 69% at 30years.
Rectal cancer in Lynch syndrome should be managed like any other rectal cancer in terms of indications for multimodality ther­apy and oncologic principles. However, the need for pelvic radiation should be consid­ered when considering a TPC and IPAA.Although there is concern about mor­bidity of an IPAA after pelvic radiation, an analysis of more than 150 IPAA patients (not Lynch syndrome) who received preoperative
pelvic radiation showed no signicant eleva­tion of 30-day morbidity rate compared to patients who did not receive pelvic radiation. It is important to note, however, that data regarding the long-term functional outcome of an IPAA performed after pelvic radiation is sparse. It is also important to assiduously avoid postoperative radiation.
Another consideration in rectal cancer decision-making is the difculty of managing a metachronous colon cancer after a proctec­tomy and coloanal anastomosis. Resecting a coloanal anastomosis in a redo pelvis is chal­lenging and associated with increased mor­bidity compared to pelvic dissection at a primary total proctocolectomy.
Of course, there are functional conse­quences after an IPAA compared to a proctec­tomy and coloanal anastomosis. A patient with an IPAA can expect to have more fre­quent bowel movements and a higher inci­dence of incontinence and seepage compared to a coloanal anastomosis. The morbidity associated with pelvic dissection and ileal pouch construction must be considered. This is a technically challenging procedure and should only be performed by those with spe­cialized surgical training and expertise.
Taking all of the above information together, the decision to perform a proctec­tomy alone or a TPC and IPAA for rectal can­cer in Lynch syndrome remains controversial. The author favors TPC with IPAA for rectal cancer in healthy Lynch syndrome patients with normal sphincter function. If there is advanced disease and the likelihood of dying from recurrent disease outweighs the likeli­hood of metachronous second primary can­cer, a proctectomy should be considered. Each case must be evaluated as an individual patient. The patient’s age, medical comorbid­ities, preoperative sphincter function, and the feasibility of future surveillance compliance factor into the decision.
G. Surgical Management: Segmental Resection
Recommendations for surgical decision­making are not absolutes. Each patient needs to be considered as an individual. For colon cancer, there are situations where a segmental
474
M. F. Kalady
resection may be considered. Examples include an unhealthy patient who cannot tol­erate an extended resection or the physiologic consequences after a total colectomy (e.g. renal impairment where dehydration could lead to renal failure); other health conditions that limit life expectancy more so than the risk of a second Lynch-related colorectal can­cer; stage IV colon cancer such that risk of mortality from current disease is greater than that from metachronous cancer. Another indi­cation is patient choice in the setting of ade­quate information and counseling. There are patients who absolutely refuse the extended prophylactic colectomy and accept the need for continued intense surveillance and meta­chronous risk. For rectal cancers, the same conditions above apply, but additional con­siderations are given to sphincter function. Patients with weak sphincter function may have better bowel function after proctectomy alone compared to IPAA. A TPC and end ileostomy could also be considered for patients with poor sphincter function. One undebatable issue in the decision to do a seg­mental colectomy is the patient’s understand­ing and willingness to undergo annual colonoscopic surveillance. If a patient is not willing or non-compliant with surveillance recommendations, this is a contraindication to segmental colectomy.
H. Total Abdominal Hysterectomy and Bilateral
salpingo-oophorectomy
For women, once beyond child-bearing age or if she have decided that she has completed her family, a prophylactic TAH/BSO should be considered. A gynecologic oncologist should be part of the Lynch syndrome care team to discuss the risk, benets, and expected hor­monal changes after this operation as well as to do the surgery. Retrospective studies demon­strate risk-reduction in uterine and ovarian cancer following prophylactic TAH-BSO.
I. Education and Evaluation of at-risk Family
Members
Since Lynch syndrome is an autosomal dominantly inherited syndrome, all rst­degree relatives of an affected individual have
a 50% chance of also having Lynch syn­drome. Patients are instructed to discuss this with family members and encourage them to attend clinical appointments with the patient. Consultations of at-risk family members with the physicians and/or genetic counseling is offered and strongly encouraged. For privacy issues, the physician cannot directly reach out to at-risk family members, but should aggres­sively work through their patients to provide education and support so that family mem­bers are appropriately evaluated.
J. Post-operative Surveillance
After surgery for colorectal cancer, there are two aspects to post-operative surveil­lance. The rst is the standard of care surveil­lance after colorectal cancer resection including physical exam and history, serum CEA, and imaging at dened intervals based on cancer stage (this is outside the scope of this chapter and discussed elsewhere).
K. Post-Operative Colorectal Risk Reduction
after Colorectal Surgery
The second aspect of surveillance is inher­ent to Lynch syndrome. As the entire colorec­tum is at increased risk for developing adenocarcinoma, any remaining colon or rec­tum must be surveyed annually by endoscopy with removal of adenomas. If a segmental col­ectomy was done, then a mechanical bowel preparation is required before colonoscopy. If a total abdominal colectomy and an ileorectal anastomosis were done, then a simple enema is given before exible proctoscopy as a rou­tine ofce procedure.
Lynch Syndrome Diagnosis Without Clinical Symptoms or Phenotype
Detailed Personal and Family History (see dis­cussion in B). Education should be provided about the associated cancer risks associated with Lynch syndrome and patients are encouraged to involve family members. If the patient agrees to share information, education and counseling should be offered to all at-risk family members (see discussion in I).
61 Colonic Conditions: Lynch Syndrome
Table 61.1 Cancer Risk to Age 70in Individuals with Lynch Syndrome Compared to the General Population
Risk in general
population Cancer type Colorectal 5.5% 52–
Endometrium 2.7% 25–
Stomach <1% 6–13% 56 < 3% 63 a 70–78 Ovary 1.6% 4–24% 42.5 1–11% 46 a 42 Hepatobiliary <1% 1–4% 50–57 NR NR a NR Urinary tract <1% 1–7% 54–60 < 1% 65 a NR Small bowel <1% 3–6% 47–49 NR 54 a 59 Brain/CNS <1% 1–3% 50 NR NR a 45 Sebaceous
neoplasms Pancreas <1% 1–6% NR NR NR NR NR
Adapted from National Comprehensive Cancer Network (NCCN) Guidelines 2.2016 NR not reported
a
The combined risk for renal pelvic, stomach, ovary, small bowel, ureter and brain in PMS2 carriers is 6% to age
70years
<1% 1–9% NR NR NR NR NR
MLH1 or MSH2 MSH6 PMS2
Risk
82%
60%
Mean age of onset (years)
44–61 10–22% 54 15–
48–62 16–26% 55 15% 49
Risk Mean age of
onset (years)
Risk Mean age of
20%
onset (years) 61–66
475
L. Colorectal Cancer Risk Reduction before
Neoplasia: Surveillance Colonoscopy and Polypectomy
The management goal of Lynch syndrome patients and families is to reduce cancer development and deaths from cancer. Colonoscopy and polypectomy reduces both the incidence of cancer and deaths from can­cer in Lynch syndrome patients by 62% and 72%, respectively. Lynch syndrome adeno­mas and cancers tend to progress more rap­idly than sporadic colorectal adenomas and cancers and thus screening intervals are more frequent in Lynch syndrome. Most guide­lines recommend surveillance colonoscopy every 1–2years, starting at age 20–25. At the Cleveland Clinic Sanford R. Weiss Center, MD, Center for Hereditary Colorectal Neoplasia, we generally recommend colo­noscopy every 2 years until age 40, then yearly after that. This is because the average age of colorectal cancer in Lynch syndrome is in the early 40s. If there is colorectal can­cer at a younger age in the family, one-year intervals are started 10years earlier than the rst CRC in the family. Also, if an adenoma is detected on colonoscopy, the interval is shortened to one year.
M. Extracolonic Risk Reduction
Once a diagnosis of Lynch syndrome is established, the physician must understand the implications or cancer risk in other organ systems. This can be after the diagnosis is made following colorectal cancer resection, or with a genetic diagnosis before any clini­cal manifestations. In either situation, the approach is the same. Approximate risks of colorectal and extracolonic cancer develop­ment to age 70, compared to the general population is given in Table 61.1. After colorectal cancer, the most common cancer is endometrial cancer. Prophylactic TAH/ BSO should be considered when a woman is done child-bearing. Although there are no prospective trials that demonstrate that endometrial screening decreases cancer risk, the literature suggests a benet. Expert opin­ion recommendations include offering screening by annual pelvic exam and endo­metrial biopsy annually starting at age 30–35 years. Ovarian cancer screening should be performed at the same time by transvaginal ultrasound. Women with Lynch syndrome should be educated regarding symptoms of endometrial cancer, including abnormal uterine bleeding and pain.
476
M. F. Kalady
Similarly, there is no evidence for gastric or small bowel screening, but expert opinion recommends an esophagoduodenoscopy at age 30–35years with biopsy of the antrum and testing for H. pylori infection and treat­ment when found. If no neoplasia is seen, consideration should be given to repeat exam in 2–3years, based on individual and family risk factors. Urinalysis is a simple non-inva­sive screening test of urinary epithelial neo­plasms and should be done annually starting at age 30–35years. Microscopic hematuria should trigger further evaluation. Skin examination for sebaceous adenomas and adenocarcinomas is also a simple, non-inva­sive evaluation that is recommended annu­ally beginning at diagnosis. There are no recommendations for routine screening for cancers of the small bowel, hepatobiliary tree, or pancreas.

Suggested Reading

Bonadona V, Bonaiti B, Olschwang S, Grandjouan S,
Huiart L, Longy M, Guimbaud R, Buecher B, Bignon YJ, Caron O, Colas C, Nogues C, Lejeune-Dumoulin S, Olivier-Faivre L, Polycarpe-Osaer F, Nguyen TD, Desseigne F, Saurin JC, Berthet P, Leroux D, Duffour J, Manouvrier S, Frebourg T, Sobol H, Lasset C, Bonaiti-Pellie C, French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304–10.
Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke
CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, Levin TR, Lieberman DA, Robertson DJ, Syngal S, Rex DK.Guidelines on genetic evalu­ation and management of Lynch syndrome: a con­sensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum. 2014;57:1025–48.
Haanstra JF, de Vos Tot Nederveen Cappel WH, Gopie JP,
Vecht J, Vanhoutvin SA, Cats A, van der Zaag-Loonen HJ, Langers AM, Bergmann JH, van de Meeberg PC, Dekker E, Kleibeuker JH, Vasen HF, Nagengast FM, van Duijvendijk P. Quality of life after surgery for colon cancer in patients with Lynch syndrome: par­tial versus subtotal colectomy. Dis Colon Rectum. 2012;55:653–9.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja
K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A.Feasibility of screen-
ing for lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783–8.
Hampel H, Frankel WL, Martin E, Arnold M, Khanduja
K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A.Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851–60.
Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan
K, Aaltonen LA, Peltomaki P, De La Chapelle A, Mecklin JP. Controlled 15-year trial on screen­ing for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34.
Kalady MF, Lipman J, McGannon E, Church JM. Risk
of colonic neoplasia after proctectomy for rectal can­cer in hereditary nonpolyposis colorectal cancer. Ann Surg. 2012;255:1121–5.
Lindor NM, Rabe K, Petersen GM, Haile R, Casey G,
Baron J, Gallinger S, Bapat B, Aronson M, Hopper J, Jass J, LeMarchand L, Grove J, Potter J, Newcomb P, Terdiman JP, Conrad P, Moslein G, Goldberg R, Ziogas A, Anton-Culver H, de Andrade M, Siegmund K, Thibodeau SN, Boardman LA, Seminara D.Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deciency: familial colorec­tal cancer type X.JAMA. 2005;293:1979–85.
National Comprehensive Cancer Network Clinical prac-
tice guidelines in oncology. Genetic/familial high-risk assessment: colorectal. Version 2.2016, NCCN.org.
Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church
JM, Baron JA, Giles GG, Leggett BA, Winship I, Lipton L, Young GP, Young JP, Lodge CJ, Southey MC, Newcomb PA, Le Marchand L, Haile RW, Lindor NM, Gallinger S, Hopper JL, Jenkins MA.Metachronous colorectal cancer risk for mismatch repair gene muta­tion carriers: the advantage of more extensive colon surgery. Gut. 2011;60:950–7.
Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR,
Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, Jarvinen HJ, Moslein G, Mallorca group. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recom­mendations by a group of European experts. Gut. 2013;62:812–23.
Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman
PT, Clark MB, Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH.Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261–9.
Shawki S, Kalady MF.Recent advances in understanding
Lynch syndrome. F1000Res. 2016;5:2889.
Umar A, Boland CR, Terdiman JP, Syngal S, de la
Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez- Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal
61 Colonic Conditions: Lynch Syndrome
477
cancer (Lynch syndrome) and microsatellite instabil­ity. J Natl Cancer Inst. 2004;96:261–8.
Vasen HF, Abdirahman M, Brohet R, Langers AM,
Kleibeuker JH, van Kouwen M, Koornstra JJ, Boot H, Cats A, Dekker E, Sanduleanu S, Poley JW, Hardwick JC, de Vos Tot Nederveen Cappel WH, van der Meulen-de Jong AE, Tan TG, Jacobs MA, Mohamed FL, de Boer SY, van de Meeberg PC, Verhulst ML, Salemans JM, van Bentem N, Westerveld BD, Vecht J, Nagengast FM.One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology. 2010;138:2300–6.
Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR,
Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, Järvinen HJ, Möslein G;
Mallorca group. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recom­mendations by a group of European experts. Gut. 2013 Jun;62(6):812–23.
Vasen HF, Watson P, Mecklin JP, Lynch HT. New clini-
cal criteria for hereditary nonpolyposis colorec­tal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.Gastroenterology. 1999;116:1453–6.
You YN, Chua HK, Nelson H, Hassan I, Barnes
SA, Harrington J. Segmental vs. extended col­ectomy: measurable differences in morbidity, function, and quality of life. Dis Colon Rectum. 2008;51:1036–43.